Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | WRN | Q14191 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14296149 | 0.86 | NAAA (0.57) | NAAAGAAHTTALDH1A1CYP2C19 | |
| SCHEMBL8581054 | 0.84 | NAAA (0.48) | NAAAGAAHTTALDH1A1CYP2C19 | |
| SCHEMBL6429925 | 0.83 | MGAM (0.46) | NAAAGAACYP2C19BLMDGKA | |
| SCHEMBL8340130 | 0.82 | DGKA (0.47) | NAAAALDH1A1BLMDGKA | |
| SCHEMBL10854964 | 0.81 | CYP2C19 (0.56) | NAAAALDH1A1CYP2C19BLMTRPA1 | |
| SCHEMBL29021423 | 0.81 | MIF (0.36) | NAAAALDH1A1CYP2C19BLMTRPA1 | |
| SCHEMBL19350278 | 0.80 | NAAA (0.45) | NAAAGAAHTTALDH1A1CYP2C19 | |
| SCHEMBL20512190 | 0.80 | NAAA (0.45) | NAAAGAAHTTALDH1A1CYP2C19 | |
| SCHEMBL136377 | 0.80 | NAAA (0.45) | NAAAGAAHTTALDH1A1CYP2C19 | |
| SCHEMBL5500580 | 0.79 | DGKA (0.48) | CYP1A2BLMDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115175735-B | Antiviral compounds | 吉利德科学公司 | 2025-03-04 | — | — | CN | disclosed |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| WO-2022030469-A1 | COMPOSITION FOR FORMING RESIST UNDERLAYER FILM | 日産化学株式会社 | 2022-02-10 | — | — | WO | disclosed |
| WO-2022030468-A1 | COMPOSITION FOR FORMING RESIST UNDERLAYER FILM | 日産化学株式会社 | 2022-02-10 | — | — | WO | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9849191-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-7671095-B2 | Films and particles | THE TRUSTEES OF THE BOSTON UNIVERSITY (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080075718-A1 | Films and Particles | THE TRUSTEES OF THE BOSTON UNIVERSITY | 2008-03-27 | — | — | US | disclosed |
| US-20080075718-A1 | Films and Particles | THE TRUSTEES OF THE BOSTON UNIVERSITY | 2008-03-27 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20040248981-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | NAAA 1685/4885GAA 630/4885HTT 4160/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | NAAA 3020/4885GAA 2569/4885HTT 4197/4885 |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | NAAA 1685/4885GAA 630/4885HTT 4160/4885 |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | NAAA 3020/4885GAA 2569/4885HTT 4197/4885 |
| US-20080075718-A1 | Films and Particles | APOB, PGF, ACTB | NAAA 3310/4885GAA 836/4885HTT 581/4885 |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | NAAA 2915/4885GAA 814/4885HTT 4091/4885 |
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | NAAA 145/4885GAA 1042/4885HTT 2874/4885 |
| US-20040248981-A1 | Benzamidine derivatives | HABP2, F7, F2 | NAAA 140/4885GAA 997/4885HTT 2865/4885 |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | PREP, HCCS, PEPD | NAAA 1048/4885GAA 426/4885HTT 3278/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | NAAA 2654/4885GAA 834/4885HTT 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.